MA42844A - Combinaisons thérapeutiques comprenant des immunoconjugués anti-folr1 - Google Patents

Combinaisons thérapeutiques comprenant des immunoconjugués anti-folr1

Info

Publication number
MA42844A
MA42844A MA042844A MA42844A MA42844A MA 42844 A MA42844 A MA 42844A MA 042844 A MA042844 A MA 042844A MA 42844 A MA42844 A MA 42844A MA 42844 A MA42844 A MA 42844A
Authority
MA
Morocco
Prior art keywords
including anti
combinations including
therapeutic combinations
folr1 immunoconjugates
folr1
Prior art date
Application number
MA042844A
Other languages
English (en)
Inventor
Jan Pinkas
Jose Ponte
Rodrigo R Ruiz-Soto
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of MA42844A publication Critical patent/MA42844A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
MA042844A 2015-09-17 2016-09-16 Combinaisons thérapeutiques comprenant des immunoconjugués anti-folr1 MA42844A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562220028P 2015-09-17 2015-09-17
US201562242669P 2015-10-16 2015-10-16
US201562250756P 2015-11-04 2015-11-04

Publications (1)

Publication Number Publication Date
MA42844A true MA42844A (fr) 2018-07-25

Family

ID=58289711

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042844A MA42844A (fr) 2015-09-17 2016-09-16 Combinaisons thérapeutiques comprenant des immunoconjugués anti-folr1

Country Status (12)

Country Link
US (4) US10172875B2 (fr)
EP (1) EP3349796A4 (fr)
JP (3) JP6880006B2 (fr)
KR (1) KR20180053319A (fr)
CN (2) CN108601828B (fr)
AU (2) AU2016323968B2 (fr)
CA (1) CA2994888A1 (fr)
HK (1) HK1255141A1 (fr)
IL (2) IL298438A (fr)
MA (1) MA42844A (fr)
RU (1) RU2749865C2 (fr)
WO (1) WO2017049149A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL290617B2 (en) 2010-02-24 2023-11-01 Immunogen Inc Folate receptor 1 antibodies and immunoconjugates and uses thereof
TR201802659T4 (tr) 2011-04-01 2018-03-21 Immunogen Inc Folr1 kanser terapisinin etkinliğini arttırmak için yöntemler.
KR20200079565A (ko) 2012-08-31 2020-07-03 이뮤노젠 아이엔씨 엽산 수용체 1의 검출을 위한 진단성 검정 및 키트
CA2921975C (fr) 2013-08-30 2024-02-13 Immunogen, Inc. Anticorps et dosages pour la detection du recepteur 1 du folate
PT3055332T (pt) * 2013-10-08 2019-12-09 Immunogen Inc Regimes de dosagem de imunoconjugados anti-folr1
WO2017049149A1 (fr) 2015-09-17 2017-03-23 Immunogen, Inc. Combinaisons thérapeutiques comprenant des immunoconjugués anti-folr1
KR20200006546A (ko) * 2017-05-16 2020-01-20 이뮤노젠 아이엔씨 항-folr1 면역접합체 및 항-pd-1 항체 조합물
KR20200132900A (ko) 2018-03-13 2020-11-25 페인스 테라퓨틱스 인코포레이티드 항-폴레이트 수용체 1 항체 및 이의 용도
KR102275930B1 (ko) * 2018-03-14 2021-07-12 (주)알테오젠 Folr1에 특이적으로 결합하는 항체 및 그의 용도
CN112512587A (zh) 2018-08-06 2021-03-16 第一三共株式会社 抗体药物缀合物和微管蛋白抑制剂的组合
SG11202111109UA (en) 2019-04-29 2021-11-29 Immunogen Inc Biparatopic fr-alpha antibodies and immunoconjugates
US11878986B2 (en) * 2020-06-22 2024-01-23 National Health Research Institutes Poly heterocyclic conjugates and their pharmaceutical uses
CN113967261B (zh) * 2020-07-24 2023-02-03 中国科学院大连化学物理研究所 Folr1抑制剂的应用和治疗肝癌药物混合物
CN112794911B (zh) * 2021-04-14 2021-08-03 上海偌妥生物科技有限公司 人源化抗叶酸受体1抗体及其应用
CN114702593B (zh) * 2022-03-11 2023-12-08 苏州思萃免疫技术研究所有限公司 一种抗folr1/vegf的全人双特异性抗体及其筛选方法和应用

Family Cites Families (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
EP0028683A1 (fr) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotique C-15003 PHO et sa préparation
WO1982001188A1 (fr) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd Composes 4,5-deoxymaytansinoide et leur procede de preparation
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4563304A (en) 1981-02-27 1986-01-07 Pharmacia Fine Chemicals Ab Pyridine compounds modifying proteins, polypeptides or polysaccharides
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1989006692A1 (fr) 1988-01-12 1989-07-27 Genentech, Inc. Procede de traitement de cellules tumorales par inhibition de la fonction receptrice du facteur de croissance
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US20030229208A1 (en) 1988-12-28 2003-12-11 Protein Design Labs, Inc. Humanized immunoglobulins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6916605B1 (en) 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
ATE275198T1 (de) 1991-12-02 2004-09-15 Medical Res Council Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken.
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
AU3737893A (en) 1992-03-05 1993-10-05 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
US20030148406A1 (en) 1992-03-17 2003-08-07 David John King Multivalent antigen-binding proteins
DE69231123T2 (de) 1992-03-25 2001-02-15 Immunogen Inc Konjugaten von Zell-bindender Mittel und Derivaten von CC-1065
CA2163345A1 (fr) 1993-06-16 1994-12-22 Susan Adrienne Morgan Anticorps
US6696248B1 (en) 1995-08-18 2004-02-24 Morphosys Ag Protein/(poly)peptide libraries
DK0859841T3 (da) 1995-08-18 2002-09-09 Morphosys Ag Protein/(poly)peptidbiblioteker
JP2002514895A (ja) 1995-09-28 2002-05-21 アレクション、ファーマスーティカルズ、インコーポレーテッド ブタ細胞相互作用タンパク質
US6596850B1 (en) 1998-01-30 2003-07-22 Ixsys, Incorporated Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US7365166B2 (en) 1997-04-07 2008-04-29 Genentech, Inc. Anti-VEGF antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
ES2273415T3 (es) 1997-04-07 2007-05-01 Genentech, Inc. Anticuerpos anti-vegf.
CA2354862A1 (fr) 1998-10-19 2000-04-27 Yeda Research And Development Co. Ltd. Traitement du lupus erythemateux systemique par regulation negative de la reponse auto-immune a des autoantigenes
US20040031072A1 (en) 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
DK1133565T3 (da) 1999-07-02 2011-01-24 Morphosys Ag Generering af specifikke bindingspartnere til (poly)peptider, som der kodes for af genomiske DNA-fragmenter eller EST'er
IT1307309B1 (it) 1999-12-30 2001-10-30 Enea Ente Nuove Tec Peptidi stabilizzanti, polipeptidi ed anticorpi che li comprendono.
US7033594B2 (en) 2000-03-31 2006-04-25 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
DE10037759A1 (de) 2000-08-03 2002-07-04 Gruenenthal Gmbh Screeningverfahren
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
ES2309167T3 (es) 2001-02-19 2008-12-16 Merck Patent Gmbh Metodo para identificar epitotes de celulas t y metodo para preparar moleculas con inmunogenicidad reducida.
WO2002071928A2 (fr) 2001-03-14 2002-09-19 Millennium Pharmaceuticals, Inc. Molecules d'acide nucleique et proteines destinees a l'identification, l'evaluation, la prevention et la therapie du cancer des ovaires
WO2002087424A2 (fr) 2001-05-02 2002-11-07 Purdue Research Foundation Traitement et diagnostic de maladies associees aux macrophages
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US7314974B2 (en) 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
EP1486566A4 (fr) 2002-03-01 2005-10-12 Japan Enviro Chemicals Ltd Proteines capables de se lier aux hormones sexuelles feminines et procede de preparation
RS52488B (en) 2002-03-13 2013-02-28 Biogen Idec Ma Inc. ANTI-ALFAvBETA6 ANTITELA
US7531522B2 (en) 2002-04-22 2009-05-12 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Antibodies, recombinant antibodies, recombinant antibody fragments and fusions mediated plant disease resistance against fungi
AU2003295411A1 (en) 2002-11-07 2004-06-03 Celltech R & D Human monoclonal antibodies to heparanase
EP1481993A1 (fr) 2003-05-28 2004-12-01 Xerion Pharmaceuticals AG Modulation de la fonction du récepteur du poliovirus
WO2004082463A2 (fr) 2003-03-17 2004-09-30 Medical College Of Ohio Modulation de gene par recepteur de folate pour diagnostic et therapie de cancer
US20050255114A1 (en) 2003-04-07 2005-11-17 Nuvelo, Inc. Methods and diagnosis for the treatment of preeclampsia
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
CN1802388B (zh) 2003-05-09 2011-01-05 杜克大学 Cd20特异抗体及使用它们的方法
KR101441358B1 (ko) 2003-05-14 2014-09-24 이뮤노젠 아이엔씨 약물 콘쥬게이트 조성물
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
KR20120104408A (ko) 2003-05-30 2012-09-20 제넨테크, 인크. 항-ｖｅｇｆ 항체를 사용한 치료
KR20060030066A (ko) 2003-07-02 2006-04-07 제넨테크, 인크. 종양의 진단 및 치료를 위한 조성물 및 방법
WO2005054469A1 (fr) 2003-12-05 2005-06-16 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health Anticorps monoclonaux anti-sars
EP2316857A1 (fr) 2004-02-12 2011-05-04 Morphotek, Inc. Anticorps monoclonaux spécifiques pour le récepteur de folate alpha
EP1747462A2 (fr) 2004-04-27 2007-01-31 Galapagos N.V. Proc d s, agents, et analyses de criblage de compos s permettant d'induire une diff renciation de cellules mammaliennes non diff renci es en ost oblastes
EP1685161A1 (fr) 2004-08-30 2006-08-02 Lonza Biologics plc Chromatographie d'affinite plus chromatographie par echanges d'ions pour la purification des anticorps
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
US7776869B2 (en) 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
CA2584859C (fr) 2004-10-25 2017-11-07 Merck & Co., Inc. Anticorps anti-addl et leurs utilisations
US20070294782A1 (en) 2004-12-21 2007-12-20 Mark Abad Transgenic plants with enhanced agronomic traits
EP1833510A4 (fr) 2004-12-27 2010-02-10 Progenics Pharmaceuticals Neva Anticorps antitoxines d'administration orale et leurs procedes de fabrication et d'utilisation
AP2007004034A0 (en) 2004-12-31 2007-06-30 Genentech Inc Polypeptides sthat bind br3 and uses thereof
EP1850866A4 (fr) 2005-01-27 2009-07-08 Univ California Anticorps monoclonaux thérapeutiques neutralisant les neurotoxines botuliques
CA2599301A1 (fr) * 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. Nouvel usage d'un compose de sulfonamide en combinaison avec un inhibiteur de l'angiogenese
DK2343320T3 (da) 2005-03-25 2018-01-29 Gitr Inc Anti-gitr-antistoffer og anvendelser deraf
US7608413B1 (en) 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
RU2007139912A (ru) 2005-03-30 2009-05-10 Пердью Рисерч Фаундейшн (Us) Способ прогнозирования течения рака на основе количественного анализа клеточного рецептора витамина фолата
JP2009521206A (ja) 2005-04-22 2009-06-04 モルフォテック、インク． 免疫エフェクター活性を有する葉酸受容体アルファ陽性細胞に内部移行する抗体
US7786266B2 (en) 2005-05-12 2010-08-31 Oncotherapy Science, Inc. Methods for damaging cells using effector function of anti-DSC2 antibody
EP1915394B1 (fr) 2005-05-20 2021-01-27 Lonza Biologics plc. Expression de niveau eleve d'un anticorps recombinant d'une cellule hote de mammifere
AU2006250888A1 (en) 2005-05-24 2006-11-30 Avesthagen Limited A method for the production of a monoclonal antibody to CD20 for the treatment of B-cell lymphoma
JP5175723B2 (ja) 2005-07-05 2013-04-03 パーデュー・リサーチ・ファウンデーション 単球介在性疾患を治療するための組成物の調製
US7521195B1 (en) 2005-07-21 2009-04-21 Celera Corporation Lung disease targets and uses thereof
WO2007022416A2 (fr) 2005-08-18 2007-02-22 Ramot At Tel Aviv University Ltd. Anticorps monocatenaires diriges contre le peptide $g(b)-amyloide
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP4938263B2 (ja) 2005-08-19 2012-05-23 独立行政法人農業生物資源研究所 一本鎖抗体によるサイトゾルタンパク質の機能阻害法およびその利用
CA2620802A1 (fr) 2005-08-31 2007-03-08 Schering Corporation Anticorps anti-il-23 obtenus par genie genetique
US8044179B2 (en) 2005-09-13 2011-10-25 National Research Council Of Canada Methods and compositions for modulating tumor cell activity
US20090162374A1 (en) * 2005-09-14 2009-06-25 Geraghty Daniel E Specific removal of activated immune cells
CA2625403A1 (fr) 2005-10-17 2007-04-26 Institute For System Biology Glycoproteines derivees de tissus et du serum et leurs methodes d'utilisation
EP1790664A1 (fr) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Anticorps monoclonaux contre claudin-18 pour le traitement du cancer
SG170749A1 (en) 2005-12-20 2011-05-30 Sbi Biotech Co Ltd Anti-ilt7 antibody
KR20080110833A (ko) 2006-03-21 2008-12-19 와이어쓰 아밀로이드 형성 질환의 예방 및 치료 방법
WO2007143561A1 (fr) 2006-06-01 2007-12-13 Mayo Foundation For Medical Education And Research Immunité vis-a-vis des récepteurs de folate
CN101490084A (zh) * 2006-06-06 2009-07-22 健泰科生物技术公司 抗dll4抗体及其使用方法
WO2007147265A1 (fr) 2006-06-23 2007-12-27 Alethia Biotherapeutics Inc. Séquences de polynucléotides et de polypeptides impliquées dans le cancer
US7910702B2 (en) 2006-07-28 2011-03-22 The Governors Of The University Of Alberta Recombinant antibodies to sclerotinia antigens
CA2660286A1 (fr) 2006-08-09 2008-02-21 Homestead Clinical Corporation Proteines specifiques d'organes et procedes d'utilisation
NZ599144A (en) 2006-09-08 2013-10-25 Abbott Lab Interleukin -13 binding proteins
EP1900752A1 (fr) 2006-09-15 2008-03-19 DOMPE' pha.r.ma s.p.a. Anticorps monoclonaux humains et ses fragments liant spécifiquement le récepteur alpha de l'acide folique pour l'immunothérapie du cancer de l'ovaire
AU2007312367B2 (en) 2006-10-12 2012-09-06 Chugai Seiyaku Kabushiki Kaisha Diagnosis and treatment of cancer using anti-EREG antibody
CA2670471A1 (fr) * 2006-11-22 2008-06-05 Adnexus, A Bristol-Myers Squibb R&D Company (A Delaware Corporation) Substances therapeutiques a base de proteines modifiees ciblees sur des recepteurs de tyrosine kinases, dont l'igf-ir
EP2103628A4 (fr) 2006-12-14 2012-02-22 Forerunner Pharma Res Co Ltd Anticorps monoclonal anti-claudine 3, et traitement et diagnostic du cancer au moyen d'un tel anticorps
WO2008076487A2 (fr) 2006-12-20 2008-06-26 Verenium Corporation Anticorps: procédé de fabrication et d'utilisation
US20080227704A1 (en) 2006-12-21 2008-09-18 Kamens Joanne S CXCL13 binding proteins
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
EP2609934A1 (fr) 2007-02-16 2013-07-03 KTB Tumorforschungsgesellschaft mbH Récepteur et promédicament ciblé antigène
US20100104626A1 (en) 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
CN103396489A (zh) 2007-02-23 2013-11-20 默沙东公司 工程改造的抗IL-23p19抗体
WO2008145136A1 (fr) 2007-05-30 2008-12-04 Aarhus Universitet Inactivation des stat3 par inhibition de la voie du récepteur des folates
US9138484B2 (en) 2007-06-25 2015-09-22 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
CN101139613B (zh) 2007-08-01 2011-06-08 姜荣锡 抗肿瘤二元多肽及其应用与制备方法
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
AU2008334912B8 (en) 2007-12-12 2013-10-24 Pincell Srl Remedies for Pemphigus Containing Anti Fas Ligand antibodies
JP5660900B2 (ja) 2007-12-21 2015-01-28 ノバルティス アーゲー 有機化合物
HUE024291T2 (en) 2007-12-26 2016-01-28 Biotest Ag Immunoconjugates and Applications for CD138
CA2711557A1 (fr) 2008-01-11 2009-07-16 The University Of Tokyo Anticorps anti-cldn6
US8093364B2 (en) 2008-01-18 2012-01-10 Bio-Rad Laboratories, Inc. Enhanced purification of antibodies and antibody fragments by apatite chromatography
WO2009094456A2 (fr) * 2008-01-22 2009-07-30 Johns Hopkins University Utilisation de médicaments à base d'oxazaphosphorine après-transplantation, à dose élevée, pour la réduction d'un rejet de greffe
WO2009132081A2 (fr) 2008-04-24 2009-10-29 The Research Foundation Of State University Of New York Ciblage à base d’anticorps monoclonaux des récepteurs de folate
CN104524592B (zh) 2008-04-30 2018-06-05 伊缪诺金公司 交联剂和它们的用途
CN104258413A (zh) 2008-04-30 2015-01-07 伊缪诺金公司 有效的偶联物和亲水性连接体
US8383351B2 (en) 2008-06-11 2013-02-26 Oxford Brookes University Antibody to inhibin/ activin β-B subunit
NZ592255A (en) 2008-09-17 2013-07-26 Endocyte Inc Folate receptor binding conjugates of antifolates
WO2010033913A1 (fr) 2008-09-22 2010-03-25 Icb International, Inc. Anticorps, analogues et leurs utilisations
CN101440130B (zh) 2008-11-21 2011-07-27 中国人民解放军第四军医大学 一种抗人IL-13Rα2单克隆抗体的重链和轻链的可变区
EP2378876B1 (fr) 2008-12-19 2018-11-14 Medicis Pharmaceutical Corporation Formulations d'imiquimode à faible force de dosage et schémas posologiques courts pour traiter la kératose actinique
JP5923035B2 (ja) 2009-03-24 2016-05-24 バイオセプト インコーポレイティッド 細胞の捕捉および解析のデバイスおよび方法
ES2624835T3 (es) 2009-08-06 2017-07-17 Immunas Pharma, Inc. Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos
AU2010305374A1 (en) 2009-10-09 2012-05-03 Sanofi Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
EP2526118A4 (fr) * 2010-01-21 2013-11-13 Immunogen Inc Compositions et procédés pour le traitement du cancer ovarien
WO2011100398A1 (fr) 2010-02-10 2011-08-18 Immunogen, Inc. Anticorps anti-cd20 et leurs utilisations
MX369170B (es) * 2010-02-23 2019-10-30 Genentech Inc Combinación concurrente de un anticuerpo anti-vegf con carboplatino y gemcitabina para usarse en el tratamiento de cáncer ovárico.
IL290617B2 (en) 2010-02-24 2023-11-01 Immunogen Inc Folate receptor 1 antibodies and immunoconjugates and uses thereof
EP2550295A1 (fr) 2010-03-24 2013-01-30 F. Hoffmann-La Roche AG Anticorps anti-lrp6
JP2013523843A (ja) * 2010-04-15 2013-06-17 ベジェニクス ピーティーワイ リミテッド Ｖｅｇｆ−ｃ拮抗剤を用いた併用治療
BR112013009275A2 (pt) * 2010-10-20 2017-06-20 Morphotek Inc glicoformas de anticorpo alfa de receptor anti-folato
EP2635304B1 (fr) 2010-11-05 2017-03-08 Morphotek, Inc. Récepteur alpha de folate à titre de marqueur diagnostique et pronostique des cancers exprimant un récepteur alpha de folate
ES2672238T3 (es) * 2011-01-26 2018-06-13 Allergan, Inc. Composición androgénica para el tratamiento de una afección oftálmica
MX2013011201A (es) 2011-03-29 2013-12-16 Immunogen Inc Proceso para la elaboracion de conjugados de mejor homogeneidad.
EP2691155B1 (fr) 2011-03-29 2018-11-14 Immunogen, Inc. Préparation de conjugués de maytansinoïde anticorps par procédé en une étape
TR201802659T4 (tr) 2011-04-01 2018-03-21 Immunogen Inc Folr1 kanser terapisinin etkinliğini arttırmak için yöntemler.
US20120282282A1 (en) 2011-04-04 2012-11-08 Immunogen, Inc. Methods for Decreasing Ocular Toxicity of Antibody Drug Conjugates
US9156854B2 (en) * 2011-04-18 2015-10-13 Immunogen, Inc. Maytansinoid derivatives with sulfoxide linker
EP2524929A1 (fr) 2011-05-17 2012-11-21 Sanofi Utilisation d'anticorps immunoconjugués anti-CD19 maytansinoïdes pour le traitement de symptômes de malignités CD19+lymphocytes B
PL2731972T3 (pl) 2011-07-15 2018-06-29 Eisai R&D Management Co., Ltd. Przeciwciała skierowane przeciwko receptorowi folianowemu alfa i ich zastosowania
US9296819B2 (en) * 2012-06-12 2016-03-29 Promis Neurosciences Inc. Antibodies and conjugates that target misfolded prion protein
KR20200079565A (ko) 2012-08-31 2020-07-03 이뮤노젠 아이엔씨 엽산 수용체 1의 검출을 위한 진단성 검정 및 키트
WO2014055842A1 (fr) 2012-10-04 2014-04-10 Immunogen, Inc. Procédé de préparation de conjugués maytansinoïdes anticorps stables
EP2930240B1 (fr) 2012-12-07 2018-08-01 Kyowa Hakko Kirin Co., Ltd. Anticorps anti-folr1
AU2014251045B2 (en) * 2013-04-08 2019-06-13 Berg Llc Treatment of cancer using coenzyme Q10 combination therapies
CA2911499A1 (fr) 2013-05-14 2014-11-20 Immunogen, Inc. Schemas posologiques d'immunoconjugues anti-folr1
WO2014205342A2 (fr) * 2013-06-20 2014-12-24 Morphotek, Inc. Procédé pour le traitement d'un cancer de l'ovaire
CA2921975C (fr) 2013-08-30 2024-02-13 Immunogen, Inc. Anticorps et dosages pour la detection du recepteur 1 du folate
PT3055332T (pt) * 2013-10-08 2019-12-09 Immunogen Inc Regimes de dosagem de imunoconjugados anti-folr1
WO2015149018A1 (fr) 2014-03-28 2015-10-01 Immunogen, Inc. Schémas posologiques d'immunoconjugués anti-folr1
WO2017049149A1 (fr) * 2015-09-17 2017-03-23 Immunogen, Inc. Combinaisons thérapeutiques comprenant des immunoconjugués anti-folr1

Also Published As

Publication number Publication date
AU2016323968B2 (en) 2023-07-06
CA2994888A1 (fr) 2017-03-23
CN116440279A (zh) 2023-07-18
US11033564B2 (en) 2021-06-15
IL298438A (en) 2023-01-01
IL257531A (en) 2018-04-30
JP2018527383A (ja) 2018-09-20
IL257531B2 (en) 2023-04-01
EP3349796A4 (fr) 2019-05-29
RU2749865C2 (ru) 2021-06-17
EP3349796A1 (fr) 2018-07-25
CN108601828A (zh) 2018-09-28
CN108601828B (zh) 2023-04-28
RU2018111205A3 (fr) 2019-10-17
US20200397806A1 (en) 2020-12-24
JP6880006B2 (ja) 2021-06-02
US20220168326A1 (en) 2022-06-02
KR20180053319A (ko) 2018-05-21
HK1255141A1 (zh) 2019-08-09
AU2023233173A1 (en) 2023-10-12
IL257531B (en) 2022-12-01
RU2018111205A (ru) 2019-10-17
AU2016323968A1 (en) 2018-03-01
US20190167704A1 (en) 2019-06-06
WO2017049149A1 (fr) 2017-03-23
US20170095571A1 (en) 2017-04-06
US10172875B2 (en) 2019-01-08
JP2021107452A (ja) 2021-07-29
JP2023101813A (ja) 2023-07-21

Similar Documents

Publication Publication Date Title
MA42844A (fr) Combinaisons thérapeutiques comprenant des immunoconjugués anti-folr1
HK1256383A1 (zh) 治療劑
DK3107563T3 (da) Glycomålrettede terapeutiske midler
GB201509893D0 (en) Therapeutic agents
BR112016018062A2 (pt) compostos terapêuticos, composição farmacêutica e usos
BR112018005409A2 (pt) terapêutica de glicodirecionamento.
MA39483A (fr) Agents thérapeutiques cibles
GB201517263D0 (en) Therapeutic agents
GB201410816D0 (en) Therapeutic agents
DK3393478T3 (da) Kombinationsterapi
GB201603104D0 (en) Therapeutic agents
DK3215607T3 (da) Phagterapi
DK3408265T3 (da) Terapeutiske forbindelser
GB201502412D0 (en) Therapeutic use
GB201608797D0 (en) Therapeutic use
GB201410815D0 (en) Therapeutic agents
GB201410817D0 (en) Therapeutic agents
GB201509885D0 (en) Therapeutic agents
DK3302478T3 (da) Pac-1 kombinations behandling
GB201509888D0 (en) Therapeutic agents
DK3280447T3 (da) Farmaceutiske formuleringer
GB201513299D0 (en) Therapeutic agents
DK3795130T3 (da) Terapiapparat.
DK3329004T3 (da) Terapeutiske oligonukleotider
GB201521767D0 (en) Therapeutic agents